Mortality of lymphoma and myeloma in China, 2004-2017: an observational study
Open Access
- 3 March 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 12 (1), 22
- https://doi.org/10.1186/s13045-019-0706-9
Abstract
BackgroundThere is a dearth of accurate information about patterns of mortality of lymphoid neoplasms and temporal trends in China. In this nationwide mortality study, we aimed to assess the mortality of lymphoma and myeloma in 2017 and the changes in the trend from 2004 to 2016.MethodsDeath certificate data obtained from the Chinese Center for Disease Control and Prevention's disease surveillance points system (CDC-DSP) and population data from the National Bureau of Statistics of China were used in this study. We described the mortality of lymphoma and myeloma in 2017 by age group, sex, residence, and region and evaluated the temporal trend from 2004 to 2016 using joinpoint regression.ResultsAn estimated 52,000 deaths associated with lymphoma and myeloma occurred in 2017. The age-standardized mortality rate China (ASMRC) and age-standardized mortality rate worldwide (ASMRW) per 100,000 were 3.74 and 2.60, respectively. Males had higher ASMRC than females (4.54 vs. 2.91 per 100,000). The ASMRC in urban areas was significantly higher than that in rural areas (4.35 vs. 3.47 per 100,000). The age-specific mortality rate showed an upward trend with age and reached a maximum in the age group of over 85years. In terms of regional variation, Eastern China had the highest mortality rate (3.43/100,000), followed by Central China (3.10/100,000) and Western China (3.02/100,000). The mortality rates of lymphoma and myeloma increased annually by 4.5% during the period 2004-2016, with a significant rapid upward trend in rural areas since 2007.ConclusionsThe mortality of lymphoma and myeloma increased in China from 2004 to 2017. The rapid increase in disease burden in rural areas highlights new challenges for disease prevention and control strategies.Keywords
Funding Information
- Capital’s Funds for Health Improvement and Research (2018-1-2151)
This publication has 32 references indexed in Scilit:
- Under-5 mortality in 2851 Chinese counties, 1996–2012: a subnational assessment of achieving MDG 4 goals in ChinaThe Lancet, 2015
- Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Propensity score weighting for addressing under-reporting in mortality surveillance: a proof-of-concept study using the nationally representative mortality data in ChinaPopulation Health Metrics, 2015
- Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research NetworkBritish Journal of Cancer, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Cancer survival in China, 2003–2005: A population‐based studyInternational Journal of Cancer, 2014
- Financial protection effects of modification of China’s New Cooperative Medical Scheme on rural households with chronic diseasesBMC Health Services Research, 2014
- Challenges to effective cancer control in China, India, and RussiaThe Lancet Oncology, 2014
- Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional studyThe Lancet, 2012
- China’s Rural-Urban Care Gap Shrank For Chronic Disease Patients, But Inequities PersistHealth Affairs, 2010